[{"NetIncomeLoss_2_Q2_USD":-189592000.0,"EquitySecuritiesFvNiGainLoss_1_Q2_USD":70683000.0,"IndefiniteLivedIntangibleAssetsExcludingGoodwill_0_Q2_USD":0.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":172878000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":173406000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_0_Q2_USD":23100000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"LiabilitiesNoncurrent_0_Q2_USD":67864000.0,"InventoryFinishedGoodsNetOfReserves_0_Q2_USD":20045000.0,"OperatingLeaseRightOfUseAssetAmortizationExpense_2_Q2_USD":5114000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":1468000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-55113000.0,"Depreciation_2_Q2_USD":16571000.0,"StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_1_Q2_USD":0.0,"AssetsCurrent_0_Q2_USD":1330582000.0,"SellingGeneralAndAdministrativeExpense_2_Q2_USD":247891000.0,"SellingGeneralAndAdministrativeExpense_1_Q2_USD":125642000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":31485000.0,"CommonStockSharesIssued_0_Q2_shares":173865000.0,"Assets_0_Q2_USD":2164556000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":-2010000.0,"OtherComprehensiveIncomeLossNetOfTax_2_Q2_USD":1239000.0,"ShareBasedCompensation_2_Q2_USD":68406000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":61637000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"EquitySecuritiesFvNiGainLoss_2_Q2_USD":11604000.0,"InterestReceivableCurrent_0_Q2_USD":1700000.0,"ProvisionForDoubtfulAccounts_2_Q2_USD":0.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":-2042000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":198077000.0,"FiniteLivedIntangibleAssetsAccumulatedAmortization_0_Q2_USD":10400000.0,"ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_2_Q2_USD":372000000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_0_Q2_USD":23100000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_Q2_USD":-57000.0,"AccountsReceivableNetCurrent_0_Q2_USD":290074000.0,"NumberOfReportableSegments_2_Q2_Segment":1.0,"CommonStockValue_0_Q2_USD":174000.0,"InvestmentIncomeNet_2_Q2_USD":5124000.0,"InvestmentIncomeNet_1_Q2_USD":2092000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":53271000.0,"CostsAndExpenses_2_Q2_USD":718832000.0,"CostsAndExpenses_1_Q2_USD":371963000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_2_Q2_USD":194733000.0,"IncreaseDecreaseInInventories_2_Q2_USD":4070000.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-188353000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-23200000.0,"AmortizationOfIntangibleAssets_1_Q2_USD":4700000.0,"AmortizationOfIntangibleAssets_2_Q2_USD":4736000.0,"OtherAssetsNoncurrent_0_Q2_USD":17089000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":117320000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":63663000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":3485265000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2_Q2_USD":53271000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":1231000.0,"OperatingLeaseLiability_0_Q2_USD":73868000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":13623000.0,"CommonStockSharesAuthorized_0_Q2_shares":250000000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":512512000.0,"CommonStockSharesOutstanding_0_Q2_shares":173865000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_0_Q2_USD":23100000.0,"PaymentsToAcquireMarketableSecurities_2_Q2_USD":574700000.0,"DebtSecuritiesAvailableForSaleChangeInPresentValueExpenseReversal_2_Q2_USD":0.0,"DebtSecuritiesAvailableForSaleChangeInPresentValueExpenseReversal_1_Q2_USD":0.0,"FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_0_Q2_USD":23100000.0,"Goodwill_0_Q2_USD":274671000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":40174000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_Q2_USD":8000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q2_USD":32000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-155343000.0,"InventoryRawMaterialsNetOfReserves_0_Q2_USD":69957000.0,"LiabilitiesCurrent_0_Q2_USD":282615000.0,"AccountsPayableCurrent_0_Q2_USD":59226000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":117320000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":54838000.0,"OperatingLeaseWeightedAverageDiscountRatePercent_0_Q2_pure":0.053,"EquitySecuritiesFvNiRealizedGainLoss_2_Q2_USD":11604000.0,"FiniteLivedIntangibleAssetsNet_0_Q2_USD":295289000.0,"OperatingLeasePayments_2_Q2_USD":6896000.0,"OperatingLeasePayments_1_Q2_USD":3560000.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"CapitalExpendituresIncurredButNotYetPaid_2_Q2_USD":10400000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":185288000.0,"NetIncomeLoss_1_Q2_USD":-21190000.0,"IncreaseDecreaseInAccountsReceivable_2_Q2_USD":54073000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-157242000.0,"LeaseCost_1_Q2_USD":4661000.0,"LeaseCost_2_Q2_USD":9109000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":277998000.0,"OperatingIncomeLoss_2_Q2_USD":-206320000.0,"OperatingIncomeLoss_1_Q2_USD":-93965000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":778348000.0,"InventoryNet_0_Q2_USD":90002000.0,"FiniteLivedIntangibleAssetsGross_0_Q2_USD":305700000.0,"PreferredStockValue_0_Q2_USD":0.0,"OperatingLeaseCost_2_Q2_USD":7135000.0,"OperatingLeaseCost_1_Q2_USD":3589000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":2164556000.0,"PreferredStockSharesAuthorized_0_Q2_shares":5000000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":10205000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":393276000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0_Q2_USD":11600000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-1.1,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.12,"OtherLiabilitiesNoncurrent_0_Q2_USD":4201000.0,"StockholdersEquity_0_Q2_USD":1814077000.0,"DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_0_Q2_USD":0.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":47146000.0,"FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_0_Q2_USD":23100000.0,"LongTermInvestments_0_Q2_USD":0.0,"IncreaseDecreaseInOtherOperatingLiabilities_2_Q2_USD":29337000.0,"VariableLeaseCost_2_Q2_USD":1974000.0,"VariableLeaseCost_1_Q2_USD":1072000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-1672830000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2_Q2_USD":1500000.0,"IncreaseDecreaseInContractWithCustomerLiability_2_Q2_USD":0.0,"Ticker":"SGEN","CIK":"1060736","name":"SEATTLE GENETICS INC \/WA","OfficialName":"Seagen Inc. Common Stock","form":"10-Q","period":"20200630","fy":"2020.0","fp":"Q2","qtrs":"2","uom":"USD","footnote":"nan","Market Cap":"26523270348.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Biological Products (No Diagnostic Substances)","Market":"NASDAQ","SP500":"nan","filed":"20200731"}]